Hepatorenal Syndrome

Newly published research from the United Kingdom demonstrates terlipressin is effective for improving kidney function in hospitalized patients with hepatorenal syndrome type 1.

The FDA has accepted a new drug application for terlipressin, a medication that could be used to treat hepatorenal syndrome type 1, according to a press release from biopharmaceutical company Mallinckrodt.

Patients with liver disease, especially those with advanced liver disease, may face comorbid renal-related complications including impaired renal function and hepatorenal syndrome. Liver disease and kidney care have also been tied lately between use of hepatitis C-infected kidneys in nonviremic patients.

BOSTON — In this exclusive video from The Liver Meeting 2019, Arun Sanyal, MD, professor of medicine at Virginia Commonwealth University, discusses results of the CONFIRM trial, which demonstrated that terlipressin was effective in improving renal function and achieving hepatorenal syndrome reversal in a significant percentage of patients with hepatorenal syndrome type 1.

Initial results from a phase 3 clinical study of terlipressin showed that the therapy met its primary endpoint of “verified” hepatorenal syndrome type 1 reversal, according to a press release from Mallinckrodt.